Leflunomide (Arava) in early rheumatoid arthritis
https://doi.org/10.14412/1995-4484-2005-38
Abstract
Objective. To assess efficacy and safety of leflunomide in the treatment of early rheumatoid arthritis (RA). Material and methods. 30 pts with RA aged 18 to 67 years were examined. 17 pts with disease duration less than 6 months (mean 3,6±2,6 months) were included in group 1 and 13 pts with disease duration from 6 months to 3 years (mean 1,8+1,3 years) - in group 2. DAS 28, ACR criteria, patient's general health, pain, HAQ, Keitel functional test and laboratory indices were used as outcome measures. Leflunomide was administered 20 mg/day during 12 months. Results. Significant decrease of RA activity indices was achieved during 3 months in both groups. Group 1 pts showed progressive improvement during the whole period of the treatment. Group 2 pts had the most prominent decrease of activity after 6 months of the treatment. Later some of them showed tendency to deterioration of several parameters. In 10 (58,8%) pts of group I clinical remission was achieved by the 6th month. The treatment was stopped because of adverse events in 4 pts. Serious adverse events were absent. Conclusion. Leflunomide (arava) is a highly effective and well tolerated disease modifying drug for the treatment of early RA. Leflunomide was more effective in pts with disease duration less than 6 months.
References
1. <div><p>Балабанова P.M. Руководство по внутренним болезням. Ревматические болезни. Под ред. В.А. Насоновой и Н.В. Бунчука, М., Медицина, 1997, С.257</p><p>Шостак Н.А., (под ред В.А. Насоновой и Н.В. Бунчука), М., Мурадянц А.А, Логинова Т.К., Тимофеев ВТ. Кпинико- иммуиологические особенности раннего ревматоидного артрита. Научно-практич. ревматол., 2004, 1, 15-17.</p><p>Fries J.F. Current treatment paradigms in rheumatoid arthritis. J. Rheumatology (Oxford), 2000, 39, 30-35</p><p>Emery P., Salmon M. Early rheumatoid arthritis: time to aim for remission? Ann. Rheum, Dis., 1995, 54, 944-947</p><p>Guidelines for the management of rheumatoid arthritis: 2002 update. Arthr. Rheum., 2002, 46, 2, 328-346</p><p>Сальникова T.C. Сравнительная оценка эффективности делапша, сульфасалазина и метотрексата на ранней стадии ревматоидного артрита. Дисс. к.м.н., М., 2003.</p><p>Чичасова Н.В. Ревматоидный артрит: клинико-лабораторные и клинико-морфологические сопоставления, прогноз. Дисс. д.м.н., М., 2000.</p><p>Mladenovich V., Domljan Z., Razman В. et al. Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis: results of randomized, placebo-controlled, phase II study. Arthr. Rheum., 1995, 38, 1595-1630</p><p>Smolen J.S., Emery P., Kalden J.R. et al. The Efficacy of Leflunomide Monotherapy in Rheumatoid Arthritis: Towards the Goals of Disease Modifying Antirheumatic Drug Therapy J. Rheumatol., 2004, 71, 13-20.</p><p>Kalden J.R., Schattenkirchner М., Sorensen H. et al. The efficacy and safety ofleflunomide in patients with active rheumatoid arthritis: a five-year followup study. Arthr. Rheum. 2003, 48, 1513-1520.</p><p>Cohen S., Wfeaver A., Schiff М., Strand V. Two-year treatment of active RA with luflunomide compared with placebo or methotrexate. Arthr. Rheum. 1999, 159, 2542-2550</p><p>Smolen J.S. Kalden J.R., Scott D.L. et al. Efficacy and safety of leflunomide compared with placebo and sulfasalazine in active rheumatoid arthritis: a double-blind, randomized, multicentre trial. European Leflunomide Study Group. Lancet., 1999, 353, 259-266</p><p>Emery P., Breeveld F.C., Lemmel E.M. et al. A comparation ol the efficacy and safety ofleflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology (Oxford), 2000, 39, 655-665.</p><p>Standt V., Cohen S., ShifT M. et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Arch. Intern. Med., 1999, 159, 2542-2550</p><p>Scott D.L., Smolen J.S., Kalden J.R. et al. Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double-blind, placebo-controled trial versus sulfasalazine. Ann. Rheum. Dis., 2001, 60, 913-923</p><p>Cohen S., Cannon G., SchifTM. et al. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of leflunomide in the Treatment of Rheumatoid Arthritis Investigator Group. Arthr. Rheum., 2001,44,1984-1992</p><p>Kalden J.R., Scott D.L., Smolen J.S. et al. Improved functional ability in patients with rheumatoid arthritis - longterm treatment with leflunomide versus sulfasalazine. European Leflunomide Study Group. J. Rheumatol., 2001, 28, 1983-1991</p><p>Балабанова P.M., Маколкин В.И., Шостак Н.А., Чичасова Н.В. и др. Динамика показателей воспалительной активности у больных ревматоидным артритом на разных этапах терапии лефлуномидом. Тер. архив, 2004, 5, 28-32</p><p>Иванова М.М., Каратеев Д.Е., Шакирова М.Р., Смирнов А.В. Оценка результатов длительного лечения больных ревматоидным артритом солями золота, аминохинолиновыми препаратами и нестероидными противовоспалительными препаратами. Тер. архив, 1997, 5, с.27-32</p><p>Scott D., Schattenkirchner М., Smolen J.S. et al. Efficacy of leflunomide versus placebo, versus SSA in RA. Effect of disease duration. Arthr. Rheum., 1998, 41, S155.</p></div><br />
Review
For citations:
Balabanova R.V., Karateev D.E., YKashevarov R., Luchihina E.L. Leflunomide (Arava) in early rheumatoid arthritis. Rheumatology Science and Practice. 2005;43(5):31-34. (In Russ.) https://doi.org/10.14412/1995-4484-2005-38
Views:
4272
Email this article 